Skip to content

ACTAVIA LIFE SCIENCES, INC.: 10-Q filed 2024-05-20

What ACTAVIA LIFE SCIENCES, INC. reported in its quarterly report filed 2024-05-20 (fiscal Q2 2024): 21 published measures, 68 facts as tagged in accession 0001213900-24-045020.

This filing

Form
10-Q (quarterly report)
Filed
2024-05-20
Fiscal period
fiscal Q2 2024
Accession
0001213900-24-045020 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ACTAVIA LIFE SCIENCES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-03-3148,614USD
At 2023-09-3095,657USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-03-31-2,181,749USD
At 2023-12-31-2,103,546USD
At 2023-09-30-1,955,909USD
At 2023-03-31-1,870,275USD
At 2022-12-31-1,809,641USD
At 2022-09-30-1,688,597USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-95,518USD91
2023-10-01 to 2024-03-31-243,155USD183
2023-01-01 to 2023-03-31-4,129,200USD90
2022-10-01 to 2023-03-31-4,279,044USD182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-10-01 to 2024-03-31-83,085USD183
2022-10-01 to 2023-03-31-25,157USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-10-01 to 2024-03-319,491USD183
2022-10-01 to 2023-03-31-11,985USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-03-31-28,906,757USD
At 2023-09-30-28,663,602USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-01-01 to 2024-03-31771,811,360shares91
2023-10-01 to 2024-03-31771,811,360shares183
2023-01-01 to 2023-03-31588,518,916shares90
2022-10-01 to 2023-03-31384,249,138shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-01-01 to 2024-03-31771,811,360shares91
2023-10-01 to 2024-03-31771,811,360shares183
2023-01-01 to 2023-03-31588,518,916shares90
2022-10-01 to 2023-03-31384,249,138shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-01-01 to 2024-03-310USD/shares91
2023-10-01 to 2024-03-310USD/shares183
2023-01-01 to 2023-03-310USD/shares90
2022-10-01 to 2023-03-310USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-01-01 to 2024-03-310USD/shares91
2023-10-01 to 2024-03-310USD/shares183
2023-01-01 to 2023-03-310USD/shares90
2022-10-01 to 2023-03-310USD/shares182

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-01-01 to 2023-03-313,858,793USD90
2022-10-01 to 2023-03-313,858,793USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-71,387USD91
2023-10-01 to 2024-03-31-196,117USD183
2023-01-01 to 2023-03-31-3,966,452USD90
2022-10-01 to 2023-03-31-4,089,264USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-03-312,230,363USD
At 2023-09-302,051,566USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-01-01 to 2024-03-3171,387USD91
2023-10-01 to 2024-03-31196,117USD183
2023-01-01 to 2023-03-313,966,452USD90
2022-10-01 to 2023-03-314,089,264USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-01-01 to 2024-03-3111,226USD91
2023-10-01 to 2024-03-3129,743USD183
2023-01-01 to 2023-03-3113,704USD90
2022-10-01 to 2023-03-3131,660USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-03-31771,811,360shares
At 2023-09-30771,811,360shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-03-311,392USD
At 2023-09-3074,986USD
At 2023-03-312,221USD
At 2022-09-3039,363USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-03-3125,953,197USD
At 2023-09-3025,935,882USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-03-3147,222USD
At 2023-09-3020,671USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-03-3160,161USD91
2023-10-01 to 2024-03-31166,374USD183
2023-01-01 to 2023-03-3193,955USD90
2022-10-01 to 2023-03-31198,811USD182

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-24,131USD91
2023-10-01 to 2024-03-31-47,038USD183
2023-01-01 to 2023-03-31-162,748USD90
2022-10-01 to 2023-03-31-189,780USD182

Inspect the source

Entity
ACTAVIA LIFE SCIENCES, INC. / CIK 0001582249
Captured
SEC response SHA-256
1fa3da8551fa6523f67ea25c9d27ef0c331ae8c1fcbc6eda23b86adc30a6f71c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001582249.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))